Literature DB >> 7192598

Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine.

J P Bergerat, B Drewinko, P Corry, B Barlogie, D H Ho.   

Abstract

cis-Dichlorodiammineplatinum(II) and 1-beta-D-arabinofuranosylcytosine display a dramatic synergistic effect when tested in simultaneous combination on LoVo cells, a human colon carcinoma cell line. 1-beta-D-Arabinofuranosylcytosine alone does not induce any cytotoxicity on LoVo cells even at high concentrations but is able to increase up to 1000 times the lethal effects of cis-dichlorodiammineplatinum(II). DNA elution experiments show that 1-beta-D-arabinofuranosylcytosine increases the amount of cis-dichlorodiammineplatinum(II)-induced DNA cross-links. The possible mechanisms of this effect are discussed, and some explanations are proposed.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7192598

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  17 in total

1.  Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

Authors:  J L Abbruzzese; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; E G de Vries; H Schraffordt Koops; P H Willemse
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 3.  A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation.

Authors:  R J Fram
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

4.  Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.

Authors:  Frank Kroschinsky; Denise Röllig; Barbara Riemer; Michael Kramer; Rainer Ordemann; Johannes Schetelig; Martin Bornhäuser; Gerhard Ehninger; Mathias Hänel
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-28       Impact factor: 4.553

5.  Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.

Authors:  D J Stewart; Z Grahovac; H Hugenholtz; V DaSilva; M T Richard; B Benoit; G Belanger; N Russell
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

Review 6.  Drug resistance and DNA repair.

Authors:  M Fox; J J Roberts
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice.

Authors:  G Pratesi; L Gianni; C Manzotti; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 8.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.

Authors:  B Jeremic; L Djuric; L Mijatovic
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

10.  Cisplatin plus cytosine arabinoside in adults with malignant gliomas.

Authors:  D J Stewart; M T Richard; B Benoit; H Hugenholtz; N Russell; J Dennery; E Peterson; Z Grahovac; G Belanger; S Aitkens
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.